A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00666575
Recruitment Status : Completed
First Posted : April 25, 2008
Last Update Posted : April 25, 2008
Information provided by:

Brief Summary:
The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness

Condition or disease Intervention/treatment Phase
Transient Insomnia Drug: Gabapentin Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Actual Use Study of the Safety and Tolerability of Gabapentin 500 mg in a Potential OTC Population
Study Start Date : December 2004
Actual Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Gabapentin Drug: Gabapentin
Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days

Placebo Comparator: Placebo Drug: Placebo
Matched placebo oral capsule 30 minutes prior to bedtime for 28 days

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: Day 45 ]

Secondary Outcome Measures :
  1. Pulse and Blood Pressure [ Time Frame: Day 45 ]
  2. Subjective proportion of nights having difficulty sleeping [ Time Frame: Day 45 ]
  3. Subjective Sleep Latency [ Time Frame: Day 45 ]
  4. Subjective Wake After Sleep Onset [ Time Frame: Day 45 ]
  5. Subjective Number of Awakenings [ Time Frame: Day 45 ]
  6. Subjective Total Sleep Time [ Time Frame: Day 45 ]
  7. Subjective Assessment of Sleep Quality [ Time Frame: Day 45 ]
  8. Subjective Assessment of Ease of Awakening [ Time Frame: Day 45 ]
  9. Subject Global Evaluation [ Time Frame: Day 45 ]
  10. Pittsburg Sleep Quality Index [ Time Frame: Day 45 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects >/= 12 years of age who reported occasional sleeplessness in month prior to screening

Exclusion Criteria:

  • Females who were pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00666575

United States, Alabama
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85018
United States, California
Pfizer Investigational Site
Beverly Hills, California, United States, 90211
Pfizer Investigational Site
San Francisco, California, United States, 94102
United States, Florida
Pfizer Investigational Site
Clearwater, Florida, United States, 33765
Pfizer Investigational Site
Deland, Florida, United States, 32720
Pfizer Investigational Site
New Port Richey, Florida, United States, 34652
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33024
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33409
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30328
United States, Idaho
Pfizer Investigational Site
Boise, Idaho, United States, 83704
Pfizer Investigational Site
Boise, Idaho, United States, 83712
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46250
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89104
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89128
United States, New Mexico
Pfizer Investigational Site
Santa Fe, New Mexico, United States, 87505
United States, Tennessee
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78705
Pfizer Investigational Site
Fort Worth, Texas, United States, 76135
Pfizer Investigational Site
San Antonio, Texas, United States, 78205
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84102
Pfizer Investigational Site
West Jordan, Utah, United States, 84088
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00666575     History of Changes
Other Study ID Numbers: A9451146
First Posted: April 25, 2008    Key Record Dates
Last Update Posted: April 25, 2008
Last Verified: April 2008

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
gamma-Aminobutyric Acid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents
GABA Agents